Full Press Release Details
electroCore Announces First Quarter 2024 Financial Results
Record first quarter 2024 net sales of $5.4 million, an increase of 96% over first quarter 2023
Company to host a conference call and webcast today, May 8, 2024 at 4:30 PM EST
ROCKAWAY, NJ, May 8, 2024 (GLOBE NEWSWIRE) - electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company and wellness company, today announced first quarter 2024 financial results.
First Quarter 2024 Financial Results
For the quarter ended March 31, 2024, electroCore reported net sales of $5.4 million compared to $2.8 million during the same period of 2023, which represents an approximately 96% increase over the prior year. The increase of $2.7 million is primarily due to an increase in net sales across all major channels.
| (in thousands) | Three months ended March 31, | % Change | ||||||||
| Channel | 2024 | 2023 | ||||||||
| Rx gammaCore - VA/DoD | $ | 3,875 | $ | 1,705 | 127% | |||||
| Rx gammaCore - U.S. Commercial | 433 | 430 | 1% | |||||||
| Outside the United States | 449 | 410 | 10% | |||||||
| Truvaga | 385 | 147 | 162% | |||||||
| Total Before TAC-STIM | 5,142 | 2,692 | 91% | |||||||
| TAC-STIM | 301 | 88 | 242% | |||||||
| Total Revenue | $ | 5,443 | $ | 2,780 | 96% |
Gross profit for the first quarter of 2024 was $4.6 million as compared to $2.3 million for the first quarter of 2023. Gross margin was 84% for the first quarter of 2024 and 2023.
Total operating expenses in the first quarter of 2024 were approximately $8.4 million as compared to $8.5 million in the first quarter of 2023.
Research and development expense in the first quarter of 2024 was $399,000 as compared to $1,800,000 in the first quarter of 2023. This decrease was primarily due to a significant reduction in investments associated with the development of Truvaga Plus.
Selling, general and administrative expense in the first quarter of 2024 was $8.0 million as compared to $6.7 million in the first quarter of 2023. The increase was driven by continued targeted investments in sales and marketing to support our commercial efforts.
GAAP net loss in the first quarter of 2024 was $3.5 million or a loss of $0.53 per share, compared to the $5.9 million net loss or a loss of $1.24 per share in the first quarter of 2023. This significant improvement was primarily due to the increase in net sales to $5.4 million for the first quarter of 2024 compared to $2.8 million during the same period of 2023.
Adjusted EBITDA net loss in the first quarter of 2024 was $3.1 million as compared to adjusted EBITDA net loss of $5.1 million in the first quarter of 2023. These improved results are also primarily due to the 96% increase in first quarter 2024 net sales over the first quarter of 2023.
The Company defines adjusted EBITDA net loss as GAAP net loss, adjusted to exclude non-operating gains/losses, depreciation and amortization, stock-compensation expense, inventory reserve charges, severance and other related charges, legal fees associated with stockholders' litigation, and provision/benefit from income taxes. A reconciliation of GAAP net loss to Non-GAAP adjusted EBITDA net loss has been provided in the financial statement tables included in this press release.
Cash, cash equivalents and restricted cash at March 31, 2024 totaled approximately $8.1 million, as compared to approximately $10.6 million as of December 31, 2023.
Webcast and Conference Call Information
electroCore's management team will host a conference call today, May 8, 2024, beginning at 4:30 PM EST. Investors interested in listening to the conference call, or webcast may dial 877-407-8835 for domestic callers or 201-689-8779 for international callers, using Conference ID: 13744118, or click through the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=abuNgBai.
An archived webcast of the event will be available on the "Investors" section of the company's website at: www.electrocore.com.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and
wellness company dedicated to improving health through its non-invasive vagus
nerve stimulation ("nVNS") technology platform. Our focus is the
commercialization of medical devices for the management and treatment of
certain medical conditions and consumer product offerings utilizing nVNS to
promote general wellbeing and human performance in the United States and select
For more information, visit www.electrocore.com.
Forward-Looking Statements
press release and other written and oral statements made by representatives of
electroCore may contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such forward-looking
statements include, but are not limited to, statements about, electroCore's
business prospects and clinical and product development plans; its pipeline or
potential markets for its technologies; the timing, outcome and impact of
regulatory, clinical and commercial developments; business prospects around its
prescription gammaCore product, general wellness Truvaga and TAC-STIM
products, and other potential new products and markets, and other
statements that are not historical in nature, particularly those that utilize
terminology such as "anticipates," "will," "expects," "believes," "intends," and
other words of similar meaning, derivations of such words and the use of future
dates. Actual results could differ from those projected in any forward-looking
statements due to numerous factors. Such factors include, among others, the
ability to raise the additional funding needed to continue to pursue
electroCore's business and product development plans, the inherent
uncertainties associated with developing new products or technologies, the
ability to commercialize gammaCore, TAC-STIM, and Truvaga, electroCore's
results of operations and financial performance, inflation and currency
fluctuations, and any expectations electroCore may have with respect thereto,
competition in the industry in which electroCore operates and overall economic
and market conditions. Any forward-looking statements are made as of the date
of this press release, and electroCore assumes no obligation to update the
forward-looking statements or to update the reasons why actual results could
differ from those projected in the forward-looking statements, except as
required by law. Investors should consult all of the information set forth
herein and should also refer to the risk factor disclosure set forth in the
reports and other documents electroCore files with the SEC available at www.sec.gov.
ECOR Investor Relations
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
| Three months ended | ||||||||
| March 31, | ||||||||
| 2024 | 2023 | |||||||
| Net sales | $ | 5,443 | $ | 2,780 | ||||
| Cost of goods sold | 888 | 458 | ||||||
| Gross profit | 4,555 | 2,322 | ||||||
| Gross profit margin | 84% | 84% | ||||||
| Operating expenses | ||||||||
| Research and development | 399 | 1,809 | ||||||
| Selling, general and administrative | 8,005 | 6,710 | ||||||
| Total operating expenses | 8,404 | 8,519 | ||||||
| Loss from operations | ( 3,849 | ) | ( 6,197 | ) | ||||
| Other (income) expense | ||||||||
| Interest and other income | ( 225 | ) | ( 119 | ) | ||||
| Other expense | 4 | - | ||||||
| Total Other (income) expense | ( 221 | ) | ( 119 | ) | ||||
| Loss before income taxes | ( 3,628 | ) | ( 6,078 | ) | ||||
| Benefit from income taxes | 122 | 211 | ||||||
| Net loss | $ | ( 3,506 | ) | $ | ( 5,867 | ) | ||
| Net loss per share of common stock - Basic and Diluted | $ | ( 0.53 | ) | $ | ( 1.24 | ) | ||
| Weighted average common shares outstanding - Basic and Diluted | 6,617 | 4,743 |
Condensed Consolidated Balance Sheet Information
| March 31, 2024 | December 31, 2023 | |||||||
| Cash and cash equivalents | $ | 7,849 | $ | 10,331 | ||||
| Restricted cash | $ | 250 | $ | 250 | ||||
| Total assets | $ | 13,890 | $ | 16,102 | ||||
| Current liabilities | $ | 7,827 | $ | 8,123 | ||||
| Total liabilities | $ | 9,394 | $ | 8,660 | ||||
| Total stockholders' equity | $ | 4,496 | $ | 7,442 |
(Unaudited) Use of Non-GAAP Financial Measure
The Company is presenting adjusted EBITDA net loss because
it believes this measure is a useful indicator of its operating performance.
Management uses this non-GAAP measure principally as a measure of the Company's
core operating performance and believes that this measure is useful to
investors because it is frequently used by the financial community, investors,
and other interested parties to evaluate companies in the Company's industry.
The Company also believes that this measure is useful to its management and
investors as a measure of comparative operating performance from period to
period. Additionally, the Company believes its use of non-GAAP adjusted EBITDA
net loss from operations facilitates management's internal comparisons to
historical operating results by factoring out potential differences caused by
gains and charges not related to its regular, ongoing business, including,
without limitation, non-cash charges and certain large and unpredictable
charges such as restructuring expenses.
The Company defines adjusted EBITDA net loss as GAAP net
loss, adjusting to exclude non-operating gains/losses, depreciation and
amortization, stock-compensation expense, inventory reserve charges, severance and other related charges, legal fees associated with stockholders'
litigation, and provision/benefit from income taxes. A reconciliation of GAAP
net loss to Non-GAAP adjusted EBITDA net loss is provided in the financial
statement table below.
| Three months ended | |||||||
| March 31, | |||||||
| (in thousands) | 2024 | 2023 | |||||
| GAAP net loss | $ | ( 3,506 | ) | $ | ( 5,867 | ) | |
| Depreciation and amortization | 206 | 122 | |||||
| Stock-based compensation | 484 | 572 | |||||
| Inventory reserve charge | - | 75 | |||||
| Severance and other related charges | - | 332 | |||||
| Legal fees associated with stockholders' litigation | 69 | - | |||||
| Interest and other (income) expense | ( 221 | ) | ( 119 | ) | |||
| Benefit from income taxes | ( 122 | ) | ( 211 | ) | |||
| Adjusted EBITDA net loss | $ | ( 3,090 | ) | $ | ( 5,096 | ) |
The Company's use of a non-GAAP measure has limitations as
an analytical tool, and you should not consider it in isolation or as a
substitute for analysis of its results as reported under GAAP. Some of these
limitations are: (i) the non-GAAP measure does not reflect interest or tax
payments that may represent a reduction in cash available; (ii) although
depreciation and amortization are non-cash charges, the assets being
depreciated and amortized may have to be replaced in the future, and the
non-GAAP measure does not reflect cash capital expenditure requirements for
such replacements or for new capital expenditure requirements; (iii) the
non-GAAP measure does not reflect the potentially dilutive impact of
equity-based compensation; and (iv) the non-GAAP measure does not reflect
changes in, or cash requirements for working capital needs; other companies,
including companies in electroCore's industry, may calculate adjusted EBITDA
net loss differently, effectively reducing its usefulness as a comparative measure.
Because of these and other limitations, you should consider
the non-GAAP measure together with other GAAP-based financial performance